Cell and Gene Therapy Catapult
Stevenage, United Kingdom
National Center
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
59.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
○ EMA GMP
○ MHRA GMP
Quick Facts: Cell and Gene Therapy Catapult
- Signal Score
- 59.0/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- Stevenage, United Kingdom
- Modalities
- CAR-T, Cell Therapy, AAV
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Cell and Gene Therapy Catapult
CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, AAV
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Profile-based financial assessment
SEC FilingsPrivate company
Capacity
58.0
Profile-based capacity assessment
Recent Press1 articles
Recent News 1 articles
Cell and Gene Therapy Catapult Establishes Technology Advisory Board - The Medicine Maker
Cell and Gene Therapy Catapult Establishes Technology Advisory Board The Medicine Maker
Frequently Asked Questions About Cell and Gene Therapy Catapult
What is Cell and Gene Therapy Catapult's CDMO Signal Score?
Cell and Gene Therapy Catapult has a Signal Score of 59/100, based on quality, operations, financial stability, and capacity data.
Evaluating Cell and Gene Therapy Catapult for a manufacturing program?
Use the free AI matchmaker to compare Cell and Gene Therapy Catapult against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 90.9
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.9
CAR-T, Cell Therapy, AAV, ADC, Monoclonal Antibody
OmniaBio
Hamilton, ON
Signal Score: 79.5
AAV, Lentiviral, CAR-T, Cell Therapy
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 78.6
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein
Made Scientific
Princeton, NJ
Signal Score: 59.0
CAR-T, Cell Therapy, AAV